Strides Pharma Science Limited reported strong financial results for the first quarter of FY27, with revenue increasing by 13% year-on-year to ₹12,654 million. The company also saw a 14.0% growth in Gross Margins and a 5.4% increase in EBITDA, despite facing geopolitical disruptions. Operational PAT stood at ₹1,231 million, with an Operational EPS of ₹13.4.
Strides Pharma Science Delivers Robust Q1 FY27 Performance
Strides Pharma Science Limited has announced its financial results for the first quarter of FY27, showcasing a steady performance with significant year-on-year growth. The company’s total revenue reached ₹12,654 million, marking a substantial 13.0% increase compared to the same quarter in the previous fiscal year.
Key Financial Highlights
The company’s focus on operational efficiency and strategic market positioning contributed to a 14.0% rise in Gross Margins, reaching ₹7,702 million. EBITDA for the quarter grew by 5.4% YoY to ₹2,298 million. This growth was achieved despite a reported impact of approximately ₹131 million from elevated operating and freight costs due to ongoing geopolitical situations. Strides Pharma Science continues to focus on cost optimization initiatives to mitigate these pressures.
Market Performance and Profitability
Investments in Ex-US markets have shown strong results, with a 17% YoY growth in these regions, reinforcing the company’s diversified business strategy. Operational PAT for the quarter was reported at ₹1,231 million, accompanied by an Operational EPS of ₹13.4. The reported PAT stood at ₹1,655 million, reflecting a significant 56.7% increase, largely due to the divestment of the majority stake in Pivot Path. The company also reported a reduction in net debt by ₹119 million during the quarter, with the Net Debt-to-EBITDA ratio at 1.52x.
Business Outlook
Looking ahead, Strides Pharma Science remains focused on delivering sustainable and profitable growth. The company is investing in building its portfolio across various therapeutic areas and continues to pursue new product approvals. The US market showed a steady revenue of ₹6,282 million in Q1FY27, with new product approvals expected in H2FY27. Ex-US Markets revenue grew by 17% YoY to ₹5,875 million, driven by strong performance across multiple markets.
The company also highlighted its commitment to improving its EcoVadis sustainability score, which increased by 19 points over the last year.
Source: BSE
